HAE vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HAE exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating a robust financial trajectory. While the stock is currently trading above its Graham Number ($39.87), it remains significantly undervalued relative to its growth-based intrinsic value ($107.08) and a PEG ratio of 0.92. Despite a bearish technical trend and slight revenue contraction (-2.70%), the company demonstrates exceptional operational efficiency with 28.4% earnings growth and a consistent track record of beating EPS estimates. The divergence between strong internal fundamentals and poor price performance suggests a value opportunity.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HAE vs LLY: Head-to-Head Comparison
This page compares Haemonetics Corporation (HAE) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.